HSV-2 Vaccine: Current Status and Insight into Factors for Developing an Efficient Vaccine
暂无分享,去创建一个
Wei Zhang | Wei Zhang | Xiao-Peng Zhu | Zaka S. Muhammad | Jian-Guang Wang | Wu Lin | Shi-Kun Guo | Xiaoyan Zhu | Shi-Kun Guo | Jian‐guang Wang | Wu Lin
[1] L. BenMohamed,et al. Gender-Dependent HLA-DR-Restricted Epitopes Identified from Herpes Simplex Virus Type 1 Glycoprotein D , 2008, Clinical and Vaccine Immunology.
[2] A. Wald,et al. HSV-2: in pursuit of a vaccine. , 2011, The Journal of clinical investigation.
[3] N. Bourne,et al. Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and -independent mechanisms. , 2007, Journal of reproductive immunology.
[4] A. Harandi,et al. The Mucosal Adjuvant Effect of α-Galactosylceramide for Induction of Protective Immunity to Sexually Transmitted Viral Infection1 , 2009, The Journal of Immunology.
[5] M. Stefanidou,et al. Herpes Simplex Virus 2 (HSV-2) Prevents Dendritic Cell Maturation, Induces Apoptosis, and Triggers Release of Proinflammatory Cytokines: Potential Links to HSV-HIV Synergy , 2012, Journal of Virology.
[6] R. Pyles,et al. FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection , 2009, Virology Journal.
[7] Geoffrey P Garnett,et al. .املقالة لهذه الكامل النص نهاية يف الخالصة لهذه العربية الرتجمة an Estimate of the Global Prevalence and Incidence of Herpes Simplex Virus Type 2 Infection , 2022 .
[8] T. Geijtenbeek,et al. Herpes Simplex Virus Type 2 Enhances HIV-1 Susceptibility by Affecting Langerhans Cell Function , 2010, The Journal of Immunology.
[9] Aston Liu,et al. A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy. , 2011, Vaccine.
[10] A. Nesburn,et al. Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine. , 2012, Future virology.
[11] J. Cohen,et al. A Herpes Simplex Virus 2 Glycoprotein D Mutant Generated by Bacterial Artificial Chromosome Mutagenesis Is Severely Impaired for Infecting Neuronal Cells and Infects Only Vero Cells Expressing Exogenous HVEM , 2012, Journal of Virology.
[12] Mimi Y. Kim,et al. ORIGINAL ARTICLE: Female Genital Tract Secretions Inhibit Herpes Simplex Virus Infection: Correlation with Soluble Mucosal Immune Mediators and Impact of Hormonal Contraception , 2009, American journal of reproductive immunology.
[13] Takashi Kawana,et al. [Genital herpes]. , 2009, Nihon rinsho. Japanese journal of clinical medicine.
[14] A. Nesburn,et al. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge , 2009, Mucosal Immunology.
[15] Q. Sattentau,et al. Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens , 2012, Nature Biotechnology.
[16] A. Ashkar,et al. Prolonged Exposure to Progesterone Prevents Induction of Protective Mucosal Responses following Intravaginal Immunization with Attenuated Herpes Simplex Virus Type 2 , 2003, Journal of Virology.
[17] B. Williams,et al. RNA-Dependent Protein Kinase Is Required for Alpha-1 Interferon Transgene-Induced Resistance to Genital Herpes Simplex Virus Type 2 , 2005, Journal of Virology.
[18] V. Ferreira,et al. Delayed but effective induction of mucosal memory immune responses against genital HSV-2 in the absence of secondary lymphoid organs , 2012, Mucosal Immunology.
[19] A. Wald,et al. Phase I Study of a Herpes Simplex Virus Type 2 (HSV-2) DNA Vaccine Administered to Healthy, HSV-2-Seronegative Adults by a Needle-Free Injection System , 2008, Clinical and Vaccine Immunology.
[20] A. Iwasaki,et al. Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus , 2008, The Journal of experimental medicine.
[21] J. Adler-Moore,et al. Liposomal gD ectodomain (gD1-306) vaccine protects against HSV2 genital or rectal infection of female and male mice. , 2009, Vaccine.
[22] A. Ashkar,et al. A critical role for IL‐15 in TLR‐mediated innate antiviral immunity against genital HSV‐2 infection , 2011, Immunology and cell biology.
[23] Shizuo Akira,et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. , 2006, Vaccine.
[24] K. Rosenthal,et al. Estradiol Regulates Susceptibility following Primary Exposure to Genital Herpes Simplex Virus Type 2, while Progesterone Induces Inflammation , 2005, Journal of Virology.
[25] D. Bernstein,et al. Efficacy results of a trial of a herpes simplex vaccine. , 2012, The New England journal of medicine.
[26] A. Rolland,et al. Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection. , 2012, The Journal of general virology.
[27] W. Halford,et al. Herpes Simplex Virus 2 ICP0− Mutant Viruses Are Avirulent and Immunogenic: Implications for a Genital Herpes Vaccine , 2010, PloS one.
[28] F. Eko,et al. A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes. , 2007, FEMS immunology and medical microbiology.
[29] Lei Jin,et al. Immune Surveillance by CD8αα+ Skin Resident T Cells in Human Herpesvirus Infection , 2013, Nature.
[30] A. Wald,et al. Rapidly Cleared Episodes of Oral and Anogenital Herpes Simplex Virus Shedding in HIV-Infected Adults , 2010, Journal of acquired immune deficiency syndromes.
[31] A. Wald,et al. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. , 2006, Vaccine.
[32] K. Rosenthal,et al. Protection against Genital Herpes Infection in Mice Immunized under Different Hormonal Conditions Correlates with Induction of Vagina-Associated Lymphoid Tissue , 2005, Journal of Virology.
[33] S. Delagrave,et al. High-Purity Preparation of HSV-2 Vaccine Candidate ACAM529 Is Immunogenic and Efficacious In Vivo , 2013, PloS one.
[34] D. Marciani,et al. Effect of an immune enhancer, GPI-0100, on vaccination with live attenuated herpes simplex virus (HSV) type 2 or glycoprotein D on genital HSV-2 infections of guinea pigs. , 2008, Antiviral research.
[35] J. Lubinski,et al. Live Attenuated Herpes Simplex Virus 2 Glycoprotein E Deletion Mutant as a Vaccine Candidate Defective in Neuronal Spread , 2012, Journal of Virology.
[36] C. Kaushic,et al. Increased prevalence of sexually transmitted viral infections in women: the role of female sex hormones in regulating susceptibility and immune responses. , 2011, Journal of reproductive immunology.
[37] L. BenMohamed,et al. Future viral vectors for the delivery of asymptomatic herpes epitope-based immunotherapeutic vaccines. , 2010, Future virology.
[38] Xiliang Wang,et al. Identification of B- and T-cell epitopes from glycoprotein B of herpes simplex virus 2 and evaluation of their immunogenicity and protection efficacy. , 2012, Vaccine.
[39] L. BenMohamed,et al. Immunodominant “Asymptomatic” Herpes Simplex Virus 1 and 2 Protein Antigens Identified by Probing Whole-ORFome Microarrays with Serum Antibodies from Seropositive Asymptomatic versus Symptomatic Individuals , 2012, Journal of Virology.
[40] J. Dou,et al. An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice. , 2011, Vaccine.
[41] Koanhoi Kim,et al. Modulation of protective immunity against herpes simplex virus via mucosal genetic co-transfer of DNA vaccine with β2-adrenergic agonist , 2009, Experimental & Molecular Medicine.
[42] A. Ashkar,et al. Differential induction of innate anti-viral responses by TLR ligands against Herpes simplex virus, type 2, infection in primary genital epithelium of women. , 2009, Antiviral research.
[43] D. Long,et al. An Adjuvanted Herpes Simplex Virus 2 Subunit Vaccine Elicits a T Cell Response in Mice and Is an Effective Therapeutic Vaccine in Guinea Pigs , 2013, Journal of Virology.
[44] A. Adimora,et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. , 1999, JAMA.
[45] A. Wald,et al. Phase I Dose-Escalation Study of a Monovalent Heat Shock Protein 70-Herpes Simplex Virus Type 2 (HSV-2) Peptide-Based Vaccine Designed To Prime or Boost CD8 T-Cell Responses in HSV-Naïve and HSV-2-Infected Subjects , 2008, Clinical and Vaccine Immunology.
[46] A. Iwasaki,et al. Cutting Edge: Plasmacytoid Dendritic Cells Provide Innate Immune Protection against Mucosal Viral Infection In Situ1 , 2006, The Journal of Immunology.
[47] A. Gettie,et al. Immunomodulatory effects of HSV-2 infection on immature macaque dendritic cells modify innate and adaptive responses. , 2005, Blood.
[48] Ya-Wun Yang,et al. Delivery of DNA-based cancer vaccine with polyethylenimine. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[49] L. BenMohamed,et al. Asymptomatic Human CD4+ Cytotoxic T-Cell Epitopes Identified from Herpes Simplex Virus Glycoprotein B , 2008, Journal of Virology.
[50] N. Bourne,et al. A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. , 2012, Vaccine.
[51] J. Eyles,et al. Single and Combination Herpes Simplex Virus Type 2 Glycoprotein Vaccines Adjuvanted with CpG Oligodeoxynucleotides or Monophosphoryl Lipid A Exhibit Differential Immunity That Is Not Correlated to Protection in Animal Models , 2011, Clinical and Vaccine Immunology.
[52] D. Roopenian,et al. Efficient Mucosal Delivery of Vaccine Using the FcRn-Mediated IgG Transfer Pathway , 2011, Nature Biotechnology.
[53] J. Fuchs,et al. Impact of Herpes Simplex Virus Type 2 on HIV-1 Acquisition and Progression in an HIV Vaccine Trial (the Step Study) , 2011, Journal of acquired immune deficiency syndromes.
[54] A. Iwasaki,et al. A vaccine strategy protects against genital herpes by establishing local memory T cells , 2012, Nature.
[55] J. Banchereau,et al. Functional diversity of human vaginal APC subsets in directing T cell responses , 2012, Mucosal Immunology.
[56] S. Schmechel,et al. Herpes Simplex Virus-Induced Epithelial Damage and Susceptibility to Human Immunodeficiency Virus Type 1 Infection in Human Cervical Organ Culture , 2011, PloS one.
[57] K. Lamberth,et al. HLA-A*0201-Restricted CD8+ Cytotoxic T Lymphocyte Epitopes Identified from Herpes Simplex Virus Glycoprotein D1 , 2008, The Journal of Immunology.
[58] A. Wald,et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation , 2007, The Journal of experimental medicine.
[59] L. Morrison,et al. Virus-Encoded B7-2 Costimulation Molecules Enhance the Protective Capacity of a Replication-Defective Herpes Simplex Virus Type 2 Vaccine in Immunocompetent Mice , 2008, Journal of Virology.
[60] W. Halford,et al. Loss of the Type I Interferon Pathway Increases Vulnerability of Mice to Genital Herpes Simplex Virus 2 Infection , 2010, Journal of Virology.
[61] A. Ashkar,et al. Progesterone Increases Susceptibility and Decreases Immune Responses to Genital Herpes Infection , 2003, Journal of Virology.
[62] M. Parrington,et al. Immunogenicity and Efficacy of Intramuscular Replication-Defective and Subunit Vaccines against Herpes Simplex Virus Type 2 in the Mouse Genital Model , 2012, PloS one.
[63] R. Eisenberg,et al. Three classes of cell surface receptors for alphaherpesvirus entry. , 2000, Virology.
[64] P. Spear,et al. Functional Interaction between Herpes Simplex Virus Type 2 gD and HVEM Transiently Dampens Local Chemokine Production after Murine Mucosal Infection , 2011, PloS one.
[65] Z. Cui,et al. Construction of, and T‐helper (Th)1/Th2 immune responses to, a herpes simplex virus type 2 glycoprotein D–cytotoxic T‐lymphocyte epitope DNA vaccine , 2009, Clinical and experimental dermatology.
[66] A. Wald,et al. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. , 2008, The Journal of infectious diseases.
[67] A. Iwasaki. Mucosal dendritic cells. , 2007, Annual review of immunology.
[68] Jon Cohen. Immunology. Painful failure of promising genital herpes vaccine. , 2010, Science.
[69] A. Harandi,et al. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88. , 2008, Antiviral research.
[70] Richard J Hayes,et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies , 2006, AIDS.
[71] S. Paludan,et al. Expression of Type III Interferon (IFN) in the Vaginal Mucosa Is Mediated Primarily by Dendritic Cells and Displays Stronger Dependence on NF-κB than Type I IFNs , 2010, Journal of Virology.
[72] R. Bronson,et al. Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[73] M. Motamedi,et al. Estradiol improves genital herpes vaccine efficacy in mice. , 2009, Vaccine.
[74] R. Stout,et al. Evaluation of a needle-free delivery platform for prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus 2 glycoprotein D. , 2006, Viral immunology.
[75] C. Kaushic,et al. Intranasal and subcutaneous immunization under the effect of estradiol leads to better protection against genital HSV-2 challenge compared to progesterone. , 2008, Vaccine.
[76] Sarah S. Wilson,et al. Herpes Simplex Virus Downregulates Secretory Leukocyte Protease Inhibitor: a Novel Immune Evasion Mechanism , 2008, Journal of Virology.
[77] D. Spector,et al. Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge. , 2012, Vaccine.
[78] J. Burnett,et al. A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections. , 2002, Cutis.
[79] Stephen T. C. Wong,et al. Coordination of Early Protective Immunity to Viral Infection by Regulatory T Cells , 2022 .
[80] D. Carr,et al. Herpes Simplex Virus Type 2-Induced Mortality following Genital Infection Is Blocked by Anti-Tumor Necrosis Factor Alpha Antibody in CXCL10-Deficient Mice , 2008, Journal of Virology.
[81] N. Pakravan,et al. Comparison of intramuscular and footpad subcutaneous immunization with DNA vaccine encoding HSV-gD2 in mice. , 2009, Comparative immunology, microbiology and infectious diseases.
[82] L. Brabin. Interactions of the female hormonal environment, susceptibility to viral infections, and disease progression. , 2002, AIDS patient care and STDs.
[83] S. Harrison,et al. Long-COVID Symptoms in Individuals Infected with Different SARS-CoV-2 Variants of Concern: A Systematic Review of the Literature , 2022, Viruses.
[84] S. Behar,et al. Development of a Glycoprotein D-Expressing Dominant-Negative and Replication-Defective Herpes Simplex Virus 2 (HSV-2) Recombinant Viral Vaccine against HSV-2 Infection in Mice , 2011, Journal of Virology.
[85] Larry R. Smith,et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. , 2010, Vaccine.
[86] P. Srivastava,et al. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. , 2011, Vaccine.
[87] V. Ferreira,et al. HSV-2 vaccine: current state and insights into development of a vaccine that targets genital mucosal protection. , 2013, Microbial pathogenesis.
[88] Taku Sato,et al. Interleukin 15–dependent crosstalk between conventional and plasmacytoid dendritic cells is essential for CpG-induced immune activation , 2006, Nature Immunology.
[89] Taku Sato,et al. Essential roles of DC-derived IL-15 as a mediator of inflammatory responses in vivo , 2006, The Journal of experimental medicine.
[90] K. Lingnau,et al. IC31® and IC30, novel types of vaccine adjuvant based on peptide delivery systems , 2007, Expert review of vaccines.
[91] L. Stanberry,et al. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. , 2005, The Journal of infectious diseases.
[92] T. Bergström,et al. Glycoprotein G of Herpes Simplex Virus 2 as a Novel Vaccine Antigen for Immunity to Genital and Neurological Disease , 2012, Journal of Virology.
[93] M. Bäckström,et al. Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice. , 2010, Vaccine.
[94] R. Eisenberg,et al. Herpes Simplex Virus Glycoprotein D Interferes with Binding of Herpesvirus Entry Mediator to Its Ligands through Downregulation and Direct Competition , 2010, Journal of Virology.
[95] A. Wald,et al. Evasion of the Mucosal Innate Immune System by Herpes Simplex Virus Type 2 , 2009, Journal of Virology.
[96] A. Harandi,et al. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes. , 2012, Vaccine.
[97] W. Muller,et al. Herpes Simplex Virus-2 Glycoprotein Interaction with HVEM Influences Virus-Specific Recall Cellular Responses at the Mucosa , 2012, Clinical & developmental immunology.
[98] D. Scholl,et al. HSV IgG antibody inhibits virus detection in CSF. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[99] P. Srivastava,et al. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells , 2005, Nature Immunology.
[100] W. Halford,et al. Pan-HSV-2 IgG Antibody in Vaccinated Mice and Guinea Pigs Correlates with Protection against Herpes Simplex Virus 2 , 2013, PloS one.
[101] W. Halford,et al. A Live-Attenuated HSV-2 ICP0 − Virus Elicits 10 to 100 Times Greater Protection against Genital Herpes than a Glycoprotein D Subunit Vaccine , 2011, PloS one.
[102] A. Smahi,et al. TLR3 Deficiency in Patients with Herpes Simplex Encephalitis , 2007, Science.
[103] E. Erbelding. Glycoprotein D-adjuvant vaccine to prevent genital herpes. , 2003, Current infectious disease reports.
[104] G. Doncel,et al. Herpes simplex virus and HIV: genital infection synergy and novel approaches to dual prevention , 2012, International journal of STD & AIDS.
[105] Amanda J. Lee,et al. Herpes simplex virus-2 in the genital mucosa: insights into the mucosal host response and vaccine development , 2012, Current opinion in infectious diseases.
[106] A. Ashkar,et al. NK and NKT Cell-Independent Contribution of Interleukin-15 to Innate Protection against Mucosal Viral Infection , 2005, Journal of Virology.
[107] A. Gettie,et al. HSV-2 Infection of Dendritic Cells Amplifies a Highly Susceptible HIV-1 Cell Target , 2011, PLoS pathogens.
[108] D. Bernstein,et al. Potent Adjuvant Activity of Cationic Liposome-DNA Complexes for Genital Herpes Vaccines , 2009, Clinical and Vaccine Immunology.
[109] D. Bernstein,et al. The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs. , 2010, Vaccine.
[110] K. Rosenthal,et al. Intravaginal infection with herpes simplex virus type-2 (HSV-2) generates a functional effector memory T cell population that persists in the murine genital tract. , 2010, Journal of reproductive immunology.
[111] D. Roopenian,et al. Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection , 2011, Proceedings of the National Academy of Sciences.